CNR Institutional Research Information System

SANTORO, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.252
NA - Nord America 1.252
SA - Sud America 450
EU - Europa 432
AF - Africa 30
OC - Oceania 5
Totale 4.421
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.196
SG - Singapore 984
CN - Cina 529
BR - Brasile 370
HK - Hong Kong 262
VN - Vietnam 223
FR - Francia 126
NL - Olanda 87
KR - Corea 79
DE - Germania 45
AR - Argentina 41
IT - Italia 37
JP - Giappone 37
FI - Finlandia 34
CA - Canada 27
GB - Regno Unito 26
BD - Bangladesh 24
IN - India 24
MX - Messico 18
EC - Ecuador 17
IL - Israele 12
ZA - Sudafrica 12
ES - Italia 11
ID - Indonesia 11
UA - Ucraina 10
IQ - Iraq 9
SE - Svezia 8
AT - Austria 7
CO - Colombia 7
TR - Turchia 7
KZ - Kazakistan 6
PL - Polonia 6
RU - Federazione Russa 6
OM - Oman 5
PH - Filippine 5
SA - Arabia Saudita 5
TN - Tunisia 5
UZ - Uzbekistan 5
VE - Venezuela 5
IE - Irlanda 4
LB - Libano 4
MA - Marocco 4
PK - Pakistan 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
BG - Bulgaria 3
CL - Cile 3
PY - Paraguay 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
BN - Brunei Darussalam 2
BY - Bielorussia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GT - Guatemala 2
HU - Ungheria 2
KE - Kenya 2
LT - Lituania 2
LV - Lettonia 2
NP - Nepal 2
PE - Perù 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
GU - Guam 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
LK - Sri Lanka 1
LY - Libia 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
RO - Romania 1
SR - Suriname 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 4.421
Salva come PNG Salva come JPEG
Città #
Singapore 565
Santa Clara 550
Hong Kong 261
Hefei 189
San Jose 110
Beijing 105
Lauterbourg 105
Seoul 79
Ho Chi Minh City 76
Ashburn 65
Hanoi 56
Los Angeles 48
Helsinki 34
New York 33
São Paulo 28
Tokyo 23
Dallas 22
Frankfurt am Main 21
Buffalo 17
Belo Horizonte 13
Minamishinagawa 12
Rio de Janeiro 12
Da Nang 11
Brasília 10
Haiphong 9
Bengaluru 8
Düsseldorf 8
Falkenstein 8
Johannesburg 8
Montreal 8
Orem 8
Atlanta 7
Chicago 7
Portsmouth 7
Denver 6
Dhaka 6
Guayaquil 6
Madrid 6
Milan 6
Ninh Bình 6
Quận Bình Thạnh 6
Stockholm 6
Baghdad 5
Buenos Aires 5
Campinas 5
Dublin 5
Uberaba 5
Uberlândia 5
Washington 5
Biên Hòa 4
Brooklyn 4
Elk Grove Village 4
Hangzhou 4
Houston 4
Manchester 4
Mexico City 4
Naples 4
Newark 4
Phoenix 4
Quito 4
Santo André 4
Shanghai 4
Sumaré 4
Tashkent 4
Warsaw 4
Acalanes Ridge 3
Blumenau 3
Boston 3
Chennai 3
Delhi 3
Diadema 3
Goiânia 3
Itaquaquecetuba 3
Jeddah 3
London 3
Lấp Vò 3
Maceió 3
Medford 3
Osasco 3
Paris 3
Piracicaba 3
Porto Alegre 3
Portoviejo 3
San Francisco 3
Vienna 3
Agawam 2
Almaty 2
Amsterdam 2
Andorinha 2
Ankara 2
Araraquara 2
Araruama 2
Arujá 2
Astana 2
Asunción 2
Bandar Seri Begawan 2
Barra do Piraí 2
Bauru 2
Birmingham 2
Bogotá 2
Totale 2.760
Salva come PNG Salva come JPEG
Nome #
Point mutation in GRIM-19: a new genetic lesion in Hurthle cell thyroid carcinomas. 85
The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. 81
Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase. 81
Indoleamine 2,3-Dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment 81
ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases. 76
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. 76
The b-catenin Axis Integrates Multiple Signals Downstream From RET/PTC and Leads to Cell Proliferation. 69
Attacking cancer with molecularly targeted agents Editorial overview 68
Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma 63
CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1 57
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. 56
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. 54
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. 52
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. 52
Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice 52
Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). 49
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies 49
CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. 49
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. 48
CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells. 48
Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. 48
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. 48
Identification of novel small molecule inhibitors of oncogenic RET kinase 46
Tumour Suppressor Role of the CL2/DRO1/CCDC80 Gene in Thyroid Carcinogenesis. 46
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 45
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 45
The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane 44
The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. 44
Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. 44
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. 44
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation 44
The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive. 43
Ret-mediated mitogenesis requires Src kinase activity 43
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. 43
Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma 43
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. 43
Genetics: The genomic landscape of papillary thyroid carcinoma 42
XB130 mediates cancer cell proliferation and survival through multiple signaling events downstream of Akt. 42
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma 42
Thyroid cell transformation requires the expression of the HMGA1 proteins. 42
A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. 41
TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. 41
Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia 41
RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block. 41
Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. 40
RET/PTC activation in human thyroid carcinomas 40
CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. 39
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 39
Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines 39
XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. 39
Oncogenic rearrangements driving ionizing radiation-associated human cancer 38
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. 38
BRAF is a therapeutic target in aggressive thyroid carcinoma. 38
Receptor tyrosine kinase inhibitors in thyroid cancer. 38
The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. 37
A new mechanism of BRAF activation in human thyroid papillary carcinomas. 37
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. 37
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. 36
A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. 36
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. 36
Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. 36
Critical role of the HMGI(Y) proteins in adipocytic cell growth and differentiation. 34
Pros and cons of cellular studies in developing new drugs for thyroid cancers. 33
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. 33
SOD3 Decreases Ischemic Injury Derived Apoptosis through Phosphorylation of Erk1/2, Akt, and FoxO3a. 33
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. 32
Central role of RET in thyroid cancer 32
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 31
Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. 31
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. 30
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 30
Mast cells have a protumorigenic role in human thyroid cancer. 30
Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. 29
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture 29
BAY 43-9006 inhibition of oncogenic RET mutants. 29
Minireview: RET: normal and abnormal functions 28
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. 28
Rat protein tyrosine phosphatase eta physically interacts with the PDZ domains of syntenin. 28
Low frequency of p53 mutations in human thyroid tumors: p53 and Ras mutation in two aut of fifty-six thyroid carcinomas 27
Overexpression of the HIP gene coding for a Heparin/Heparan Sulfate-binding protein in human thyroid carcinomas 27
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes 27
Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. 27
RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors. 27
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas 26
Receptor tyrosine kinases as targets for anticancer therapeutics. 26
RET/PTC oncogene activation is an early event in thyroid carcinogenesis 25
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. 25
The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 25
Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential 25
A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. 25
Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice. 25
New therapeutic approaches to treat medullary thyroid carcinoma. 25
The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive 25
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. 24
Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): Evidence for a divergence of the ERKs and JNKs pathways induced by Ret 24
Glial cell line-Derived Neurotrophic Factor differentially stimulates Ret mutants associated with the Multiple Endocrine Neoplasia type 2 syndromes and Hirschsprung's disease 24
Different mutations of the RET gene cause different human tumoral diseases 24
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenic mechanism of multiple endocrine neoplasia type 2B 24
RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. 23
Dysregulated RET signaling in thyroid cancer. 23
Totale 4.007
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.678
article - articoli 13.678
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.356
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202421 0 0 0 0 0 0 0 0 5 0 16 0
2024/20251.868 6 7 136 68 509 70 19 114 43 128 417 351
2025/20262.541 112 261 254 406 508 141 368 138 127 149 77 0
Totale 4.430